Upfront docetaxel for castration-sensitive metastatic prostate cancer in an ethnically diverse inner-city population.

被引：0
|
作者：
Pathak, Surabhi
Thekkekara, Romy Jose
Ahmed, Ahmed T.
Yadav, Udit
Mullane, Michael Russell
Batra, Kumar Kunnal
Lad, Thomas E.
Psutka, Sarah P.
机构：
[1] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA
[2] Cook Cty Hlth & Hosp Syst, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e17038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17038
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real world outcomes of upfront docetaxel for hormone naive metastatic prostate cancer in an ethnically diverse inner-city population.
    Pathak, Surabhi
    Thekkekara, Romy Jose
    Ahmed, Ahmed T.
    Yadav, Udit
    Mullane, Michael Russell
    Batra, Kumar Kunnal
    Lad, Thomas E.
    Psutka, Sarah P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [2] Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
    Isaksson, Jenny
    Green, Henrik
    Papantoniou, Dimitrios
    Pettersson, Linn
    Anden, Mats
    Rosell, Johan
    Avall-Lundqvist, Elisabeth
    Elander, Nils Oskar
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 1009 - 1022
  • [3] Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or ...
    Barata, Pedro C.
    Sartor, A. Oliver
    CANCER, 2019, 125 (11) : 1777 - 1788
  • [4] Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina, Carlo
    Messina, Marco
    Boccardo, Francesco
    EUROPEAN UROLOGY, 2018, 73 (01) : 147 - 148
  • [5] Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients
    Pathak, Surabhi
    Thekkekara, Romy
    Yadav, Udit
    Ahmed, Ahmed Tarig
    Yim, Barbara
    Lad, Thomas E.
    Mullane, Michael
    Batra, Kumar Kunnal
    Aronow, Wilbert S.
    Psutka, Sarah P.
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (04) : E380 - E387
  • [6] Effect of Upfront Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer Patients with Gleason Grade Group 5
    Yildirim, Serkan
    Yilmaz, Cengiz
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (11): : 1310 - 1314
  • [7] Chemotherapy for metastatic castration-sensitive prostate cancer
    Parimi, Sunil
    Chi, Kim N.
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (09) : 726 - 733
  • [8] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Pereira de Santana Gomes, Andrea J.
    Given, Robert
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon
    Chowdhury, Simon
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01): : 13 - 24
  • [9] Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Hizal, Mutlu
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    FUTURE ONCOLOGY, 2017, 13 (22) : 1911 - 1913
  • [10] Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel
    Shintaro Narita
    Takahiro Kimura
    Shingo Hatakeyama
    Kenichi Hata
    Takafumi Yanagisawa
    Shinya Maita
    Shuji Chiba
    Hiromi Sato
    Soki Kashima
    Atsushi Koizumi
    Ryohei Yamamoto
    Koichiro Takayama
    Katsumi Okane
    Toshiya Ishida
    Yohei Horikawa
    Teruaki Kumazawa
    Jiro Shimoda
    Takehiro Suzuki
    Chikara Ohyama
    Shin Egawa
    Tomonori Habuchi
    International Journal of Clinical Oncology, 2022, 27 : 1477 - 1486
12345